UFP Technologies: 3 Key Takeaways for Long-Term Investors

UFP Technologies reported Q3 2026 sales of $172.4 million, up 11.6% year-over-year, with gross margin improving to 29.4%. Medical technology sales grew 12.5% across diverse product lines. However, the company faces temporary margin headwinds from delayed production transfers to the Dominican Republic pending customer qualification. Management maintains a strong balance sheet with leverage under 1x and plans to pursue larger acquisitions while investing in organic growth.